A multiple-center phase II study of biweekly oxaliplatin and tegafur-uracil/leucovorin for chemonaive patients with advanced gastric cancer

Jen Shi Chen, Kun Ming Rau, Yen Yang Chen, Jen Seng Huang, Tsai Shen Yang, Yung Chang Lin, Chi Ting Liau, Kuan Der Lee, Yu Cheih Su, Ruey Ho Kao

研究成果: 雜誌貢獻文章

1 引文 (Scopus)

摘要

Purpose: The current study assessed the efficacy and safety of biweekly oxaliplatin combining oral tegafur-uracil/leucovorin in treating chemonaive patients with advanced gastric cancer. Methods: Eligible patients were 18-75 years old, had stage IV disease or post-surgery recurrence, no prior palliative chemotherapy, and an ECOG performance status of 0-2. Patients in the current study received 2-h i.v. infusion of oxaliplatin at a dose of 100 mg/m 2 after diluting in 500 mL 5% dextrose/water (dexan premedication), and 5-HT3 antagonist biweekly. Oral tegafur-uracil and leucovorin was given at a dose of 300 mg/m2/day and 60 mg/day three times daily from day 1 to 21, respectively, followed by a 1-week rest. Response assessment was based on the RECIST criteria and was performed every two courses. Toxicity was assessed according to NCI common toxicity criteria version 2. Results: From October 2003 to April 2006, 57 patients were evaluated (55 eligible) with a median age of 61 years (range 31-75). According to the assessment of response in 48 evaluable patients, partial response rate was 24/48 (50.0%) (95% CI: 35.23-64.73%) and stable disease was observed in 11 patients (22.92%), and diseased progressed in 13 patients (27.08%). Mean number of oxaliplatin cycles was 3 (0.5-6.5). Median time to progression was 177 days. Median overall survival was 318 days. Major-grade (III/IV) toxicities were diarrhea 25.5%, vomiting 16.5%, anemia 10.9%, numbness 12.7%, thrombocytopenia 7.3%, neutropenia 3.6% and leucopenia 1.8%. Conclusions: Biweekly, oxaliplatin combining oral tegafur-uracil/ leucovorin in treating patients with advanced gastric cancer showed acceptable activity and manageable toxicity.
原文英語
頁(從 - 到)819-825
頁數7
期刊Cancer Chemotherapy and Pharmacology
63
發行號5
DOIs
出版狀態已發佈 - 四月 2009
對外發佈Yes

指紋

oxaliplatin
Tegafur
Uracil
Leucovorin
Stomach Neoplasms
Toxicity
Serotonin 5-HT3 Receptor Antagonists
Chemotherapy
Surgery
Glucose
Hypesthesia
Premedication
Water
Leukopenia
Neutropenia

ASJC Scopus subject areas

  • Oncology
  • Toxicology
  • Pharmacology
  • Cancer Research
  • Pharmacology (medical)

引用此文

A multiple-center phase II study of biweekly oxaliplatin and tegafur-uracil/leucovorin for chemonaive patients with advanced gastric cancer. / Chen, Jen Shi; Rau, Kun Ming; Chen, Yen Yang; Huang, Jen Seng; Yang, Tsai Shen; Lin, Yung Chang; Liau, Chi Ting; Lee, Kuan Der; Su, Yu Cheih; Kao, Ruey Ho.

於: Cancer Chemotherapy and Pharmacology, 卷 63, 編號 5, 04.2009, p. 819-825.

研究成果: 雜誌貢獻文章

Chen, Jen Shi ; Rau, Kun Ming ; Chen, Yen Yang ; Huang, Jen Seng ; Yang, Tsai Shen ; Lin, Yung Chang ; Liau, Chi Ting ; Lee, Kuan Der ; Su, Yu Cheih ; Kao, Ruey Ho. / A multiple-center phase II study of biweekly oxaliplatin and tegafur-uracil/leucovorin for chemonaive patients with advanced gastric cancer. 於: Cancer Chemotherapy and Pharmacology. 2009 ; 卷 63, 編號 5. 頁 819-825.
@article{c14147e8468a4ac1b9a66e2e79bdd9c5,
title = "A multiple-center phase II study of biweekly oxaliplatin and tegafur-uracil/leucovorin for chemonaive patients with advanced gastric cancer",
abstract = "Purpose: The current study assessed the efficacy and safety of biweekly oxaliplatin combining oral tegafur-uracil/leucovorin in treating chemonaive patients with advanced gastric cancer. Methods: Eligible patients were 18-75 years old, had stage IV disease or post-surgery recurrence, no prior palliative chemotherapy, and an ECOG performance status of 0-2. Patients in the current study received 2-h i.v. infusion of oxaliplatin at a dose of 100 mg/m 2 after diluting in 500 mL 5{\%} dextrose/water (dexan premedication), and 5-HT3 antagonist biweekly. Oral tegafur-uracil and leucovorin was given at a dose of 300 mg/m2/day and 60 mg/day three times daily from day 1 to 21, respectively, followed by a 1-week rest. Response assessment was based on the RECIST criteria and was performed every two courses. Toxicity was assessed according to NCI common toxicity criteria version 2. Results: From October 2003 to April 2006, 57 patients were evaluated (55 eligible) with a median age of 61 years (range 31-75). According to the assessment of response in 48 evaluable patients, partial response rate was 24/48 (50.0{\%}) (95{\%} CI: 35.23-64.73{\%}) and stable disease was observed in 11 patients (22.92{\%}), and diseased progressed in 13 patients (27.08{\%}). Mean number of oxaliplatin cycles was 3 (0.5-6.5). Median time to progression was 177 days. Median overall survival was 318 days. Major-grade (III/IV) toxicities were diarrhea 25.5{\%}, vomiting 16.5{\%}, anemia 10.9{\%}, numbness 12.7{\%}, thrombocytopenia 7.3{\%}, neutropenia 3.6{\%} and leucopenia 1.8{\%}. Conclusions: Biweekly, oxaliplatin combining oral tegafur-uracil/ leucovorin in treating patients with advanced gastric cancer showed acceptable activity and manageable toxicity.",
keywords = "Chemotherapy, Gastric cancer, Leucovorin, Oxaliplatin, Tegafur-uracil",
author = "Chen, {Jen Shi} and Rau, {Kun Ming} and Chen, {Yen Yang} and Huang, {Jen Seng} and Yang, {Tsai Shen} and Lin, {Yung Chang} and Liau, {Chi Ting} and Lee, {Kuan Der} and Su, {Yu Cheih} and Kao, {Ruey Ho}",
year = "2009",
month = "4",
doi = "10.1007/s00280-008-0797-4",
language = "English",
volume = "63",
pages = "819--825",
journal = "Cancer Chemotherapy and Pharmacology",
issn = "0344-5704",
publisher = "Springer Verlag",
number = "5",

}

TY - JOUR

T1 - A multiple-center phase II study of biweekly oxaliplatin and tegafur-uracil/leucovorin for chemonaive patients with advanced gastric cancer

AU - Chen, Jen Shi

AU - Rau, Kun Ming

AU - Chen, Yen Yang

AU - Huang, Jen Seng

AU - Yang, Tsai Shen

AU - Lin, Yung Chang

AU - Liau, Chi Ting

AU - Lee, Kuan Der

AU - Su, Yu Cheih

AU - Kao, Ruey Ho

PY - 2009/4

Y1 - 2009/4

N2 - Purpose: The current study assessed the efficacy and safety of biweekly oxaliplatin combining oral tegafur-uracil/leucovorin in treating chemonaive patients with advanced gastric cancer. Methods: Eligible patients were 18-75 years old, had stage IV disease or post-surgery recurrence, no prior palliative chemotherapy, and an ECOG performance status of 0-2. Patients in the current study received 2-h i.v. infusion of oxaliplatin at a dose of 100 mg/m 2 after diluting in 500 mL 5% dextrose/water (dexan premedication), and 5-HT3 antagonist biweekly. Oral tegafur-uracil and leucovorin was given at a dose of 300 mg/m2/day and 60 mg/day three times daily from day 1 to 21, respectively, followed by a 1-week rest. Response assessment was based on the RECIST criteria and was performed every two courses. Toxicity was assessed according to NCI common toxicity criteria version 2. Results: From October 2003 to April 2006, 57 patients were evaluated (55 eligible) with a median age of 61 years (range 31-75). According to the assessment of response in 48 evaluable patients, partial response rate was 24/48 (50.0%) (95% CI: 35.23-64.73%) and stable disease was observed in 11 patients (22.92%), and diseased progressed in 13 patients (27.08%). Mean number of oxaliplatin cycles was 3 (0.5-6.5). Median time to progression was 177 days. Median overall survival was 318 days. Major-grade (III/IV) toxicities were diarrhea 25.5%, vomiting 16.5%, anemia 10.9%, numbness 12.7%, thrombocytopenia 7.3%, neutropenia 3.6% and leucopenia 1.8%. Conclusions: Biweekly, oxaliplatin combining oral tegafur-uracil/ leucovorin in treating patients with advanced gastric cancer showed acceptable activity and manageable toxicity.

AB - Purpose: The current study assessed the efficacy and safety of biweekly oxaliplatin combining oral tegafur-uracil/leucovorin in treating chemonaive patients with advanced gastric cancer. Methods: Eligible patients were 18-75 years old, had stage IV disease or post-surgery recurrence, no prior palliative chemotherapy, and an ECOG performance status of 0-2. Patients in the current study received 2-h i.v. infusion of oxaliplatin at a dose of 100 mg/m 2 after diluting in 500 mL 5% dextrose/water (dexan premedication), and 5-HT3 antagonist biweekly. Oral tegafur-uracil and leucovorin was given at a dose of 300 mg/m2/day and 60 mg/day three times daily from day 1 to 21, respectively, followed by a 1-week rest. Response assessment was based on the RECIST criteria and was performed every two courses. Toxicity was assessed according to NCI common toxicity criteria version 2. Results: From October 2003 to April 2006, 57 patients were evaluated (55 eligible) with a median age of 61 years (range 31-75). According to the assessment of response in 48 evaluable patients, partial response rate was 24/48 (50.0%) (95% CI: 35.23-64.73%) and stable disease was observed in 11 patients (22.92%), and diseased progressed in 13 patients (27.08%). Mean number of oxaliplatin cycles was 3 (0.5-6.5). Median time to progression was 177 days. Median overall survival was 318 days. Major-grade (III/IV) toxicities were diarrhea 25.5%, vomiting 16.5%, anemia 10.9%, numbness 12.7%, thrombocytopenia 7.3%, neutropenia 3.6% and leucopenia 1.8%. Conclusions: Biweekly, oxaliplatin combining oral tegafur-uracil/ leucovorin in treating patients with advanced gastric cancer showed acceptable activity and manageable toxicity.

KW - Chemotherapy

KW - Gastric cancer

KW - Leucovorin

KW - Oxaliplatin

KW - Tegafur-uracil

UR - http://www.scopus.com/inward/record.url?scp=61449100493&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=61449100493&partnerID=8YFLogxK

U2 - 10.1007/s00280-008-0797-4

DO - 10.1007/s00280-008-0797-4

M3 - Article

VL - 63

SP - 819

EP - 825

JO - Cancer Chemotherapy and Pharmacology

JF - Cancer Chemotherapy and Pharmacology

SN - 0344-5704

IS - 5

ER -